STAT+: Pharmalittle: FDA panel will scrutinize Novavax shot for Covid-19; J&J and Emergent accuse each other of breach

Top of the morning to you, and a fine one it is. Blue skies and rays of sunshine are enveloping the Pharmalot  campus, where the official mascot is bounding about the grounds in search of creatures. This means we have the opportunity to focus on the matters at hand — getting organized for another busy day and brewing cups of stimulation. Our choice is wild mountain blueberry. As always, please feel free to join us. Meanwhile, we have collected another assortment of interesting items for you to peruse as you make your way through the world. We hope your excursion is productive and meaningful. And of course, do keep in touch. Your telegrams and post cards are appreciated. …

A U.S. Food and Drug Administration advisory panel is set to scrutinize the Novavax Covid-19 vaccine after months of delays related to manufacturing problems and an agency review that found the shots effective but raised a safety concern, The Wall Street Journal writes. The meeting moves the shot one step closer to becoming available in the U.S. The FDA is expected to make a decision on authorizing the vaccine shortly, after considering the vote of its advisers. The Centers for Disease Control and Prevention would then decide whether to recommend usage. Novavax says the traditional design of its shot would appeal to people reluctant to receive Pfizer and Moderna vaccines that are based on mRNA technology.

Continue to STAT+ to read the full story…